We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$309M
AUM Growth
+$30.5M
Cap. Flow
+$16.2M
Cap. Flow %
5.24%
Top 10 Hldgs %
34.98%
Holding
101
New
36
Increased
15
Reduced
14
Closed
32

Top Buys

1
BIIB icon
Biogen
BIIB
+$12M
2
ENDP
Endo International plc
ENDP
+$10.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$10.1M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$8.63M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$7.56M

Top Sells

1
ZBH icon
Zimmer Biomet
ZBH
+$11.8M
2
CYH icon
Community Health Systems
CYH
+$7.84M
3
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$6.94M
4
CELG
Celgene Corp
CELG
+$6.92M
5
DYAX
DYAX CORPORATION
DYAX
+$5.86M

Sector Composition

1 Healthcare 85.5%
2 Financials 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYH icon
76
Community Health Systems
CYH
$465M
– –
-181,500
Closed -$7.84M
DBVT
77
DBV Technologies
DBVT
$870M
– –
-15,000
Closed -$3.5M
EXAS
78
DELISTED
Exact Sciences
EXAS
– –
-175,000
Closed -$3.85M
INGN icon
79
Inogen
INGN
$178M
– –
-110,000
Closed -$3.52M
MMSI icon
80
Merit Medical Systems
MMSI
$4.41B
– –
-300,000
Closed -$5.78M
MRK icon
81
Merck
MRK
$315B
– –
-104,800
Closed -$5.75M
PODD icon
82
Insulet
PODD
$11.4B
– –
-50,000
Closed -$1.67M
XBI icon
83
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-300,000
Closed -$22.6M
ZBH icon
84
Zimmer Biomet
ZBH
$17.6B
– –
-103,000
Closed -$11.8M
RVNC
85
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-200,000
Closed -$4.15M
EIGR
86
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-222
Closed -$1.89M
NUVA
87
CALL
DELISTED
NuVasive, Inc.
NUVA
– –
-100,000
Closed -$4.6M
AGTC
88
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-116,750
Closed -$2.33M
ADXS
89
DELISTED
Advaxis Inc
ADXS
– –
-8,333
Closed -$1.8M
TTPH
90
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-3,250
Closed -$2.38M
ACHN
91
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-375,000
Closed -$3.7M
LOXO
92
DELISTED
Loxo Oncology, Inc
LOXO
– –
-175,000
Closed -$2.18M
ENTL
93
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
– –
-150,000
Closed -$3.29M
RXDX
94
DELISTED
Ignyta, Inc.
RXDX
– –
-250,000
Closed -$2.49M
WINT
95
DELISTED
Windtree Therapeutics Inc
WINT
– –
-178,571
Closed -$2.98M
PTX
96
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-25,000
Closed -$2.67M
GBIM
97
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
– –
-68,973
Closed -$506K
DYAX
98
DELISTED
DYAX CORPORATION
DYAX
– –
-350,000
Closed -$5.86M
ZSPH
99
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-165,000
Closed -$6.94M
CELG
100
DELISTED
Celgene Corp
CELG
– –
-60,000
Closed -$6.92M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Ghost Tree Capital held 101 positions worth $309M, up 11% from $278M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ghost Tree Capital deployed $16.2M of net new capital in Q2 2015, opening 36 new positions and adding to 15 existing holdings. Its largest new stake was Biogen: 30,000 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 72% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Sage Therapeutics, an estimated $4.02M trimmed.

  • Ghost Tree Capital's largest Q2 2015 buy was Biogen: 30,000 shares worth $12.1M.
  • Ghost Tree Capital added most to Five Prime Therapeutics, Inc. in Q2 2015, an estimated $7.24M increase.
  • Ghost Tree Capital's biggest Q2 2015 reduction was Sage Therapeutics, cutting an estimated $4.02M.
  • Ghost Tree Capital fully exited Zimmer Biomet in Q2 2015, selling an estimated $11.8M.
  • Ghost Tree Capital's ten largest holdings make up 35% of its $309M portfolio in Q2 2015.
  • Ghost Tree Capital opened 36 new positions and closed 32 in Q2 2015.
  • Ghost Tree Capital's portfolio value rose 11% quarter-over-quarter to $309M.

Based on Ghost Tree Capital's 13F filing for Q2 2015, filed 14 Aug 2015.